Navigation Links
ISTA Pharmaceuticals Reports Third Quarter 2008 Financial Results
Date:10/30/2008

isks related to ISTA's ability to properly manage its growth; uncertainties and risks regarding the continued timely performance by ISTA's strategic partners of their respective obligations under existing collaborations and licensing arrangements; uncertainties and risks related to the continued availability of third party sourced products and raw materials on commercially reasonable terms, or at all; uncertainties and risks related to successful compliance with FDA and/or other governmental regulations applicable to ISTA's facilities, products and/or business; uncertainties and risks related to the scope, validity, and enforceability of patents related to ISTA's products and technologies and the impact of patents and other intellectual property rights held by third parties; and such other risks and uncertainties as detailed from time to time in ISTA's public filings with the U.S. Securities and Exchange Commission, including but not limited to ISTA's Annual Report on Form 10-K for the year ended December 31, 2007, and its Quarterly Reports on Form 10-Q for the quarters ended March 31 and June 30, 2008.

ISTA Pharmaceuticals, Inc.

Consolidated Statements of Operations

(in thousands, except per share data)

(unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

Revenue

Product sales, net $21,604 $15,796 $54,749 $39,497

License revenue 69 69 208 208

Total revenue 21,673 15,865 54,957 39,705

Cost of products sold 5,806 4,197 14,761 10,417

Gross profit margin 15,867 11,668
'/>"/>

SOURCE ISTA Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. ADVENTRX Pharmaceuticals to Report Third Quarter 2008 Results
2. Onyx Pharmaceuticals Announces Third Quarter 2008 Financial Results Teleconference and Webcast
3. PUR Water Filtration Systems Can Remove Pharmaceuticals Identified in U.S. Tap Water - More Than 99 Percent for PUR Faucet Filters and More Than 96 Percent for PUR Pitchers*
4. Morria Biopharmaceuticals Plc Announces Preliminary Results Regarding Inflammatory Markers From its Phase II Study in Allergic Rhinitis
5. Watson Pharmaceuticals Reports Third Quarter 2008 Results
6. Raptor Pharmaceuticals Corp. to Present at Two Upcoming Healthcare Conferences
7. Anadys Pharmaceuticals Commences Dosing ANA598 in Hepatitis C Patients in Phase Ib Study
8. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
9. Alexion Pharmaceuticals Chooses Blue Mountain Regulatory Asset Manager(R) for Best-in-class Calibration Management Integrated with SAP(R)
10. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
11. CoLucid Pharmaceuticals Names Linda Hogan VP of Business Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/31/2015)... RESTON, Va. (PRWEB) , ... August 31, 2015 ... ... the nation’s leading nonprofit authority on the use of health IT to ... its annual fall conference, WEDI-Con 2015 . Taking place at the Hyatt ...
(Date:8/31/2015)... Riviera Beach, FL (PRWEB) , ... August 31, 2015 , ... ... Wilander to their growing list of major sports figures who are finding joint pain ... Slam titles, and former #1 men’s tennis player in the world said, “For the ...
(Date:8/31/2015)... ... August 31, 2015 , ... PartnerTech hosted prospective ... and provided a tour of their North American facility following the S.M.A.R.T Community ... companies expanding business in the U.S. , The PartnerTech Inc. North American ...
(Date:8/31/2015)... ... August 31, 2015 , ... ERT, ... cloud analytics and workflow solutions will demonstrate multiple prototypes from its Innovation Lab ... 22-24, 2015. This is the only European event dedicated to providing case studies ...
(Date:8/31/2015)... ... 2015 , ... Global Digital Community, a UK based Digital ... now open in Jacksonville, Florida. , “We researched many opportunities in the ... waterways and beautiful beaches fit perfectly with the environment desired by our team ...
Breaking Medicine News(10 mins):Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 2Health News:WEDI Announces Program for Annual Fall Conference: WEDI-Con 2015 3Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 2Health News:Mats Wilander, 7 Grand Slam Title Winner and Tennis Legend, Now Plays Without Joint Pain 3Health News:PartnerTech Supports Economic Growth as Host 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 2Health News:ERT to Demonstrate Innovation Lab Prototypes at European PRO / eCOA Congress 3Health News:Global Digital Opens USA Digital Agency Hub 2
... By itself, dry skin isn,t a,medical worry, but serious ... and inflammation. This is one problem that hasn,t suffered,from ... dozens of,creams and lotions for dry skin. But what ... are few and far between. The fact,is that despite ...
... SAN JOSE, Calif., Jan. 29 The Coalition ... Michon as its,new Chief Executive Officer. Michon has ... of development, a key area of importance in,leadership ... will lead the,CPF,s next phase of growth, including ...
... Ray Society to add more journals and images to ... the open access publisher of peer-reviewed biomedical research has ... the GoldMiner collection. The collection now numbers over 170,000 ... search for radiology images by quickly matching search criteria ...
... Increased Resources Are an,Essential First Step, WASHINGTON, ... risk, as are the regulatory systems that oversee ... FDA Science Board report being,presented at a House ... the deficiencies to soaring demands on the FDA; ...
... that it takes 50,000 lying side by side to equal ... to be highly accurate vehicles for administering medicines and other ... what happens to the tubes after they discharge their medical ... Now, Stanford researchers, who spent months tracking the tiny tubes ...
... control the climate but unless we harness the powers of ... a losing battle, according to an article in the February ... the atmosphere. Arrogant organisms that we are, it is easy ... says Dr Dave Reay from the University of Edinburgh. In ...
Cached Medicine News:Health News:Tips for Dry Winter Skin, From the Harvard Health Letter 2Health News:CPF Appoints Mishka Michon Chief Executive Officer 2Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 2Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 3Health News:FDA Advisors Declare 'FDA Science and Mission at Risk' 4Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 2Health News:New nanotube findings by Stanford researchers give boost to potential biomedical applications 3
(Date:8/31/2015)... 2015  Soligenix, Inc. (OTCQB: SNGX) (Soligenix ... products that address unmet medical needs in the ... it has completed enrollment of the additional subjects, ... earlier this year, into the company,s Phase 2 ... defense regulator (IDR) and is being evaluated as ...
(Date:8/31/2015)... LAKE, N.J. and STAMFORD, Conn. ... U.S. pharmaceutical subsidiary of Eisai Co., Ltd., and Purdue ... a worldwide collaboration agreement for the development and commercialization ... dual orexin receptor antagonist entering Phase III clinical development ... the terms of the agreement, Eisai and Purdue Pharma ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/wmn42n/prescription_pain ) has ... Drugs - Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ ... Opportunities: 2015 - 2020 Analysis and Forecasts" ... is defined as an unpleasant sensory and emotional ... At some point, everyone experiences pain. Pain may ...
Breaking Medicine Technology:Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 2Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 3Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 4Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 5Soligenix Announces Completion of Patient Enrollment into its Phase 2 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients 6Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 2Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 3Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 4Eisai and Purdue Pharma Enter Worldwide Collaboration to Develop and Commercialize Lemborexant 5Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 2Prescription Pain Drugs Including Opioid, Anticonvulsant, Injectable/ Inhaled, Topical/ Transdermal, Medical Marijuana - 2015-2020 Analysis and Forecasts 3
... Pharmaceuticals, Inc. , a private, clinical-stage biopharmaceuticals company ... announced today that it has initiated the first ... vaccine candidate, marking the fourth human clinical trial ... program.  The Phase I dose-escalation study will assess ...
... Mass., Sept. 16 Generex Biotechnology Corporation (NasdaqCM: GNBT ... respect of the technologies and development products of its ... presentations were made at the conference Gene based ... 13 and 14, 2010 in Vienna, Austria and at ...
Cached Medicine Technology:LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 2LigoCyte Pharmaceuticals Initiates First Clinical Trial for Bivalent Intramuscular Norovirus Vaccine 3Generex Announces Presentations of Novel Vaccine Strategies 2Generex Announces Presentations of Novel Vaccine Strategies 3
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: